Research Output per year
Pneumococcal pneumonia causes over 100,000 child deaths in India annually. Uncertainty regarding the impact of introducing the pneumococcal conjugate vaccine and its high cost have been a concern, particularly after the proposed GAVI alliance support ends. We evaluate disease transmission and the vaccine’s disease and economic impact in an agent-based simulation model representative of the Indian population and healthcare system. Despite its high cost, introducing the vaccine averts a significant number of deaths and protects poor populations from financial risk.
|Number of pages||1|
|Publication status||Published - 28 Jul 2017|
|Event||INFORMS Healthcare 2017 - Rotterdam, Netherlands|
Duration: 26 Jul 2017 → 28 Jul 2017
|Conference||INFORMS Healthcare 2017|
|Period||26/07/17 → 28/07/17|
- national immunization programme
Potential impact of introducing the pneumococcal conjugate vaccine into national immunization programmes: an economic-epidemiological analysis using data from IndiaMegiddo, I., Klein, E. & Laxminarayan, R., 9 May 2018, In : BMJ Global Health. 3, 3, 12 p., e000636.
Research output: Contribution to journal › Article
Megiddo, I. (2017). Introducing the pneumococcal conjugate vaccine in India's National Immunization Programme: an economic-epidemiological analysis using agent-based modelling. Abstract from INFORMS Healthcare 2017, Rotterdam, Netherlands.